摘要
Objective： To evaluate the effect of Shugan Jianpi Granule （舒肝健脾颗粒, SJG） on the number of gut mucosal serotonin-positive cells （5-HT^＋C） in patients with irritable bowel syndrome （IBS） of stagnated Gan-qi attacking Pi （SGAP） syndrome type. Methods： Twenty-four patients were randomized equally into three groups. All were treated with the basic conventional treatment by cognition-behavior therapy with assistance of lactein 3 tablets thrice a day. Additionally, 24 g of SJG was given three times a day to group A, and the same dosage of SJG and Smecta 15 g thrice a day was given to group B, while no additional treatment was given to the control group. The number of 5-HT^＋C was measured respectively before and two weeks after treatment by immunohistochemical method. Results： The number of 5-HT^＋C decreased after treatment in all the three groups （P〈0.05）, but the decrement was more significant in the two test groups than in the control group （P〈0.05 and P〈0.01, respectively）, while comparison of 5-HT^＋C between the two test groups showed insignificant difference （P〉0.05）. Conclusion： SJG can reduce the number of 5-HT^＋C in IBS patients of SGAP syndrome type, and its effect is enhanced when used in combination with Smecta.
Objective： To evaluate the effect of Shugan Jianpi Granule （舒肝健脾颗粒, SJG） on the number of gut mucosal serotonin-positive cells （5-HT^＋C） in patients with irritable bowel syndrome （IBS） of stagnated Gan-qi attacking Pi （SGAP） syndrome type. Methods： Twenty-four patients were randomized equally into three groups. All were treated with the basic conventional treatment by cognition-behavior therapy with assistance of lactein 3 tablets thrice a day. Additionally, 24 g of SJG was given three times a day to group A, and the same dosage of SJG and Smecta 15 g thrice a day was given to group B, while no additional treatment was given to the control group. The number of 5-HT^＋C was measured respectively before and two weeks after treatment by immunohistochemical method. Results： The number of 5-HT^＋C decreased after treatment in all the three groups （P〈0.05）, but the decrement was more significant in the two test groups than in the control group （P〈0.05 and P〈0.01, respectively）, while comparison of 5-HT^＋C between the two test groups showed insignificant difference （P〉0.05）. Conclusion： SJG can reduce the number of 5-HT^＋C in IBS patients of SGAP syndrome type, and its effect is enhanced when used in combination with Smecta.
